UNSPSC 51293406: Deprodone propionate

This classification denotes the propionate form of a therapeutic glucocorticoid with the molecular structure C21H28O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, Z380L7N00P chemically known as 11.beta.,17-dihydroxypregna-1,4-diene-3,20-dione, but more commonly known as deprodone, which bears US NIH Compound Identifier 89339. European Medicines Agency schedules Deprodone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06982MIG.

UNSPSC 51293406 Deprodone propionate is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products for public health and human services programs. The work spans direct product procurement for community health initiatives, cooperative purchasing arrangements across multiple jurisdictions, and direct-to-manufacturer prescription programs designed to improve fulfillment efficiency and cost management. State agencies, county health departments, and multi-state cooperative purchasing alliances issue solicitations under this code, with issuing bodies ranging from individual counties managing community health inventories to statewide health and human services commissions orchestrating pharmacy benefit programs across large populations.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 with a March 26, 2026 response deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with awarded vendors to be provided to authorized wholesalers by May 15, 2026 and contract effectiveness on July 1, 2026.